Correlação entre a modalidade de tratamento oncológico e cirúrgico e a sobrevida em cinco anos de pacientes com diagnóstico de carcinoma de mama em uma instituição pública do estado de Sergipe

• Autor(a) principal: Feitosa, Ionara Rodrigues
• Data de Publicação: 2019
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: https://ri.ufs.br/jspui/handle/riufs/15675
• topic: Câncer de mama; Quimioterapia Neoadjuvante; Sobrevida; Breast carcinoma; Neoadjuvant chemotherapy; Survival; CIENCIAS DA SAUDE::MEDICINA

INTRODUCTION-Breast carcinoma, type with higher incidence and mortality in female, consists of a pathology where changes in the mechanisms of cell division result in dysregulated cellular proliferation. The treatment of choice is surgical removal of the tumor, followed by pre or post operative chemotherapy, radiotherapy and hormone therapy. These are the targets of research that seek to determine their influence on the survival of patients. This study aims to evaluate the correlation between chemotherapy Neoadjuvant and five-year survival of patients with breast carcinoma in one public institution of the state of Sergipe METHOD- This is a baseline cohort hospital study, performed through the review of medical records, where the variables age, staging, histological type, systemic treatment (Neoadjuvant chemotherapy or adjuvant, radiotherapy and hormone therapy) and surgery (Conservative or Total) of patients followed up at HUSE between 2011 and 2013. Survival was estimated using the Kaplan- Meier, and its correlation with variables was performed using the log-rank test. RESULTS-After exclusion, 401 patients were evaluated. There were 86 deaths, majority in stages III and IV (23.6%). Overall survival was 85%. Survival curves were similar when compared to Neoadjuvant and adjuvant (p-value = 0.500) and radical and conservative surgical treatment (p-value = 0.800). CONCLUSION- there was not a significant difference in the probability of survival in five years, the groups of patients submitted to QTNeo and patients submitted to QTAdj (p-value =0.500), as well as the group submitted to conservative surgery compared to that submitted to total mastectomy (p = 0.800). Screening through mammography and early diagnosis remain among the main measures that have an impact on reducing mortality and increasing of survival.